12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lorcaserin regulatory update

Arena submitted a response to an October 2010 complete response letter from FDA for obesity candidate lorcaserin. The response includes new data from the Phase III BLOOM-DM trial of the serotonin (5-HT2C) receptor...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >